# Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

> **NCT01709435** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 41 (actual)

## Conditions studied

- Recurrent Malignant Solid Neoplasm
- Recurrent Melanoma
- Recurrent Primary Central Nervous System Neoplasm
- Recurrent Thyroid Gland Carcinoma
- Refractory Malignant Solid Neoplasm
- Refractory Primary Central Nervous System Neoplasm
- Thyroid Gland Medullary Carcinoma

## Interventions

- **DRUG:** Cabozantinib S-malate
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01709435
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-14
- **Primary completion:** 2018-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2023-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01709435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01709435, "Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01709435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*